The twinning will focus on transferring Mendel Brain, a genetic analysis specialised in identifying a person’s biological predisposition to develop psychological traits. This approach allows professionals to screen patients and understand their genetic vulnerabilities. Recognising this risk is useful for preventing the development of emotional disorders such as depression or anxiety, providing the professional with emotional management tools. The twinning will enable Beandgo to combine the knowledge of patients’ biological profile with other parameters to personalise preventive measures. Together, both companies will obtain quality feedback to adapt their preventive guidelines. The twinning will not only provide both companies with the opportunity to test the solution in a local market but also to establish a partner relationship in the long term to launch a differential service in multiple European countries increasing their competitive strength in international markets.
